{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_relationships_comments in Relationship Comments (approximate match)
Status:
US Approved Rx
(1996)
Source:
NDA020248
(1996)
Source URL:
First approved in 1975
Source:
INTRALIPID 10% by FRESENIUS
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved OTC
Source:
21 CFR 357.210(a) cholecystokinetic corn oil, aqueous emulsion
Source URL:
First approved in 1978
Source:
NDA018081
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:labafenogene marselecobac [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00397943: Phase 2 Interventional Completed Tuberculosis
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03918629: Phase 3 Interventional Completed Clostridium Difficile Associated Disease
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE